Lian Xue, Cao Dakui, Hu Xun, Mo Weiqiang, Yao Xiujuan, Mo Juanfen, Wang Haiqin
Department of Respiratory Medicine, Bengbu Medical College, Bengbu, Anhui, 233000, People's Republic of China.
Department of Respiratory Medicine, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, 314000, People's Republic of China.
Int J Gen Med. 2022 Jun 9;15:5579-5589. doi: 10.2147/IJGM.S367999. eCollection 2022.
Lung adenocarcinoma (LUAD) is a life-threatening disease worldwide with a high mortality rate. The early diagnosis of LUAD is crucial for improving subsequent treatment and prognosis. However, biomarkers for early detection remain a clinical challenge in LUAD. Here, we aimed to develop circular RNAs (circRNAs) in circulating plasma from LUAD patients as valuable diagnostic biomarkers in LUAD.
CircRNA expression was determined by circRNA microarray in three pairs of LUAD tumour tissues and patient-matched normal lung tissues. Hsa_circ_101555 and hsa_circ_008068 were selected as potential biomarkers in LUAD tissues and plasma by RT-PCR, respectively. The diagnostic value was analysed by the area under the curve (AUC) and the receiver operating characteristic (ROC) test.
Our results showed that 6261 circRNAs were upregulated and 7238 circRNAs were downregulated in LUAD tumour tissues compared with patient-matched normal lung tissues. Hsa_circ_101555 and hsa_circ_008068 were filtered as biomarkers for early-stage LUAD. Q-PCR results showed that hsa_circ_101555 and hsa_circ_008068 were significantly upregulated in both LUAD cancer tissues and circulating plasma. Hsa_circ_101555 and hsa_circ_008068 were positively associated with tumour differentiation, tumour size and CEA (<0.05). The ROC analysis showed that hsa_circ_101555 and hsa_circ_008068 had a better diagnostic potential compared to the traditional biomarkers (CEA, SCC, CYFRA21-1) in the detection of early-stage LUAD.
The circular RNAs hsa_circ_101555 and hsa_circ_008068 could serve as novel diagnostic biomarkers for early-stage LUAD.
肺腺癌（LUAD）是一种在全球范围内威胁生命且死亡率很高的疾病。LUAD的早期诊断对于改善后续治疗及预后至关重要。然而，早期检测的生物标志物仍是LUAD临床面临的一项挑战。在此，我们旨在从LUAD患者的循环血浆中开发环状RNA（circRNA），作为LUAD中有价值的诊断生物标志物。
通过circRNA微阵列检测三对LUAD肿瘤组织及与之匹配的患者正常肺组织中的circRNA表达。通过RT-PCR分别选择hsa_circ_101555和hsa_circ_008068作为LUAD组织和血浆中的潜在生物标志物。通过曲线下面积（AUC）和受试者工作特征（ROC）检验分析诊断价值。
我们的结果显示，与患者匹配的正常肺组织相比，LUAD肿瘤组织中有6261种circRNA上调，7238种circRNA下调。hsa_circ_101555和hsa_circ_008068被筛选为早期LUAD的生物标志物。定量PCR结果显示，hsa_circ_101555和hsa_circ_008068在LUAD癌组织和循环血浆中均显著上调。hsa_circ_101555和hsa_circ_008068与肿瘤分化、肿瘤大小和癌胚抗原呈正相关（<0.05）。ROC分析显示，在早期LUAD检测中，与传统生物标志物（癌胚抗原、鳞状细胞癌抗原、细胞角蛋白19片段）相比，hsa_circ_101555和hsa_circ_008068具有更好的诊断潜力。
环状RNA hsa_circ_101555和hsa_circ_008068可作为早期LUAD的新型诊断生物标志物。
